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Abstract 1 
 2 
Adults with autism spectrum disorder (ASD) are thought to be at disproportionate risk 3 
of developing mental health comorbidities, with anxiety and depression being 4 
considered most prominent amongst these. Yet, no systematic review has been 5 
carried out to date to examine rates of both anxiety and depression focusing 6 
specifically on adults with ASD. This systematic review and meta-analysis examined 7 
the rates of anxiety and depression in adults with ASD and the impact of factors such 8 
as assessment methods and presence of comorbid intellectual disability (ID) diagnosis 9 
on estimated prevalence rates. Electronic database searches for studies published 10 
between January 2000 and September 2017 identified a total of 35 studies, including 11 
30 studies measuring anxiety (n = 26,070; mean age = 30.9, SD=6.2 years) and 29 12 
studies measuring depression (n = 26,117; mean age = 31.1, SD=6.8 years). The 13 
pooled estimation of current and lifetime prevalence for adults with ASD were 27% 14 
and 42% for any anxiety disorder, and 23% and 37% for depressive disorder. Further 15 
analyses revealed that the use of questionnaire measures and the presence of ID may 16 
significantly influence estimates of prevalence. The current literature suffers from a 17 
high degree of heterogeneity in study method and an overreliance on clinical samples. 18 
These results highlight the importance of community based studies and the 19 
identification and inclusion of well characterised samples to reduce heterogeneity and 20 
bias in estimates of prevalence for comorbidity in adults with ASD and other 21 
populations with complex psychiatric presentations.  22 
Key words: Affective Disorders; Autism; Comorbidity; Epidemiology; Prevalence.  23 
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Introduction 1 
Our understanding of the social and mental health needs of individuals with an 2 
autism spectrum disorder (ASD) across the lifespan has increased in recent years 3 
(Baxter et al. 2015), and there has been increased emphasis on better understanding 4 
these in adults (Taylor & Seltzer 2011; Howlin 2013; Moss et al. 2015, 2017). Adults 5 
with ASD are thought to be at heightened risk for several co-occurring mental health 6 
conditions, with anxiety and depressive disorders being the most prominent (Joshi et 7 
al. 2013). However, estimates of the rates of these co-occurring disorders in adults 8 
with ASD vary considerably, with some studies reporting rates of anxiety or depression 9 
as high as 70% (Charlot et al. 2008; Mazefsky et al. 2008), and others reporting rates 10 
as low as <1% for depression (Buck et al. 2014) and 5% for anxiety (Tsakanikos et al. 11 
2011).  12 
Given that ASD was, until recently, primarily considered a diagnosis of 13 
childhood, most research to date has focused on the child and adolescent years. van 14 
Steensel and colleagues published a meta-analysis of the prevalence of anxiety in 15 
young people with ASD aged <18 years of age (van Steensel et al. 2011). Their results 16 
indicated that 39.6% of young people with ASD had at least one anxiety disorder 17 
diagnosis, with specific phobias, obsessive compulsive disorder (OCD) and social 18 
anxiety being most commonly reported. Co-occurring depression in young people with 19 
ASD has so far received less attention than anxiety, possibly due to lower prevalence 20 
estimates in some studies. For instance, evidence from a population derived sample 21 
of children and adolescents with ASD reported a 3-month point prevalence of any 22 
depressive disorder to be 1.4% compared to 41.9% for any anxiety disorder (Simonoff 23 
et al. 2008). In contrast, clinical studies based on treatment seeking adults suggest 24 
that depression may indeed be common in adults with ASD, with reported rates 25 
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ranging from 20-35% (Gotham et al. 2015; Mazefsky et al. 2008). In contrast, rates in 1 
the general population are reported to be around 7% for depression, and between 1% 2 
and 12% for anxiety, depending on the specific diagnostic category (Kessler et al. 3 
2003; 2012).  4 
There are several challenges to the use of meta-analytic methods with studies 5 
on the prevalence of anxiety and depression in adults with ASD. Prominent amongst 6 
these are the lack of measures available to assess mental health comorbidities in 7 
those with ASD, particularly in adulthood, which are validated in ASD and non-ASD 8 
populations. This, along with variability in the diagnostic assessment of ASD itself and 9 
a lack of community-based studies focusing on co-occurring mental health 10 
presentations in individuals with ASD in adulthood means that there is substantial 11 
heterogeneity in both the populations being assessed and the study designs and 12 
methods/tools used to measure anxiety and depression. This is a potential caveat in 13 
the use of meta-analytic techniques as it becomes very challenging to integrate and 14 
synthesize the literature currently available. Nonetheless, describing these 15 
measurement differences enables us to quantify the degree of heterogeneity in a 16 
robust way.  17 
One important issue to consider when reviewing the available literature on 18 
mental health comorbidities in those with ASD is the problem of diagnostic over-19 
shadowing (Wood & Gadow 2010). This phenomenon has most often been discussed 20 
in relation to social phobia and OCD, which are also the most commonly reported 21 
anxiety disorders in ASD (Ozsivadjian et al. 2012; Kerns et al. 2014; Magiati et al. 22 
2017). In the case of social phobia, it has been suggested that the reduced social 23 
motivation or difficulties in social situations commonly observed in ASD can appear 24 
behaviourally similar to the anxious avoidance of social situations which is 25 
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characteristic of social phobia. In addition, compulsive behaviours in OCD can appear 1 
similar in presentation to restrictive and repetitive behaviours as observed in ASD, and 2 
indeed recent evidence has suggested some neurobiological overlap (Carlisi et al. 3 
2017). Similarly, social disinterest and/ or atypical social communication may be 4 
difficult to distinguish from psychomotor symptoms of depression in those with ASD 5 
(Chandrasekhar & Sikich 2015;  Stewart et al. 2006). 6 
Another factor that adds to the complexity of determining the rates of anxiety 7 
and depressive disorders in adults with ASD is the wide range of intellectual, verbal 8 
and adaptive functioning. With regards to intellectual functioning, for example, it has 9 
been suggested that in clinical samples approximately one third of people with ASD 10 
have intellectual functioning in the impaired range (Kim et al. 2011). Therefore, it is 11 
important to consider individuals’ functioning when considering and interpreting 12 
findings from different studies of individuals with ASD with and without intellectual 13 
disability (ID).   14 
The aim of the current systematic review and meta-analysis was to examine 15 
the rates of anxiety and depression in adults with ASD based on the literature currently 16 
available. To our knowledge, previous systematic reviews have focused solely on 17 
depression rates, have considered both children and adults together, or have included 18 
only a limited range of studies (i.e. Wigham et al. 2017; Stewart et al. 2006). Therefore, 19 
a systematic review is now required that focuses on adults, and examines both rates 20 
of depression and anxiety. Given our a-priori knowledge of a lack of community based 21 
prevalence studies in this area, we have opted to be inclusive in our selection criteria. 22 
As discussed above, the current literature has been affected by a high degree of 23 
between study heterogeneity, both in terms of the clinical populations assessed, as 24 
well as the study methodology and measures used to assess anxiety and depression. 25 
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Therefore, as well as providing the first, to our knowledge, meta-analysis of rates of 1 
anxiety and depression in adults with ASD, we aimed to explore the potential impact 2 
of ASD diagnostic measures, measures of comorbidity (i.e. clinical interviews vs 3 
questionnaire measures) and the role of intellectual disability on the estimates 4 
reported.   5 
Methods 6 
Definition/ operationalization of key constructs 7 
In the current systematic review and meta-analysis, anxiety was defined as either 8 
clinically significant/ elevated symptoms of anxiety (defined as scores above clinical cut-9 
offs on questionnaires) or a clinical diagnosis of any specific anxiety disorder (including 10 
generalized anxiety disorder; social phobia/social anxiety; specific phobia; separation 11 
anxiety; panic/agoraphobia; post-traumatic stress disorder (PTSD); or obsessive-12 
compulsive disorder (OCD)1). Most studies present panic disorder and agoraphobia as 13 
a single estimate, but in cases where they are presented separately the highest rate of 14 
the two was included. This was to reduce the chances of them being double coded due 15 
to high comorbidity, given that most articles did not specify levels of multiple comorbidity 16 
in their samples (Kessler et al. 2006).   17 
For depression, we only included cases which were above recommended clinical 18 
cut-off scores on validated questionnaires or where a professional/ clinical diagnosis of 19 
major depression was given. As an example, for the most commonly used 20 
questionnaire, the Beck Depression Inventory (BDI; Beck 1978), a cut-off score of “20” 21 
or “24”, depending on the version, or at least depression in the moderate range would 22 
                                                          
1 We have included PTSD and OCD as they have a strong anxiety component and were previously organized 
and conceptualized under anxiety disorders in DSM-IV-TR, when many of the included studies took place.  
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be required. For all other questionnaires used, their specific published cut-offs as 1 
applied by the original authors were used.  2 
Information Sources & Search approach 3 
We conducted a search of three electronic literature databases (PsycINFO, 4 
PubMed, and Web of Science) selected to provide good coverage of both medical and 5 
psychology literature. The search included publications from the start of the year 2000 6 
and ran up until 30th of September 2017. The start date was selected based on the 7 
publication of the text revision of the DSM-IV, to reduce the challenge of combining 8 
definitions from multiple diagnostic systems.  9 
The search terms used were “autis*” OR “Asperger*” OR “Pervasive 10 
Developmental Disorder”); AND (“anxi*” OR “anxiety disorder” OR “anxious”) OR 11 
(“comorbid* OR “psychiatric disorder” OR “mental health”) OR (“depress*” OR “mood 12 
disorder” OR “low mood”) AND (“adults” NOT “animal”). 13 
Two earlier systematic reviews (Stewart et al. 2006; Wigham et al. 2017) and a 14 
narrative review (Chandrasekhar & Sikich 2015) on depression in adults with ASD 15 
were also examined; and one additional citation (Crane et al. 2013) met our inclusion 16 
criteria and was included. We identified no systematic reviews or meta-analyses 17 
focusing on the prevalence of anxiety in adults with ASD. One review of comorbid 18 
Bipolar disorder was reviewed for depression related literature, but no additional 19 
citations were identified (Vannucchi et al. 2014). A Preferred Reporting Items for 20 
Systematic Reviews and Meta-analysis (PRISMA) flowchart (Figure 1) is displayed as 21 
a summary of our search and review process (see Table 1 for inclusion and exclusion 22 
criteria).  23 
INSERT FIGURE 1 ABOUT HERE 24 
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INSERT TABLE 1 ABOUT HERE 1 
Selecting studies for inclusion in the review  2 
One author (MJH) initially screened titles and abstracts for eligibility and 3 
excluded those that clearly did not meet criteria; following this, two authors (MJH & J-4 
WL) reviewed all remaining full-texts for eligibility. Disagreements were discussed and 5 
resolved on a case-by-case basis (see Reliability).  6 
Data extraction 7 
We extracted the following information from each study: a) sampling strategy; 8 
b) descriptive variables (e.g., age, gender); c) tools used to diagnose ASD; d) number 9 
of participants with an ID in the sample; e) tools used to assess anxiety/depression; f) 10 
whether diagnostic overshadowing/symptom overlap was considered in the study; and 11 
g) current and lifetime estimates of anxiety and depression.  12 
As the primary interest of this meta-analysis is on current prevalence, all 13 
sensitivity analyses were conducted on current estimates only. Three studies included 14 
both current and lifetime estimates and both were used in their respective analyses 15 
(Joshi et al. 2013; Buck et al. 2014; Gillberg et al. 2016).  16 
Reliability 17 
Selecting studies. There was good inter-rater reliability in study selection for 18 
inclusion in the review/ meta-analysis (intra-class correlation = 0.72) and all disputes 19 
were resolved by referring to the inclusion/exclusion criteria. On three occasions, the 20 
same dataset was used in data analyses in three different publications, with different 21 
subsamples from the same study being analysed (Tsakanikos et al. 2006, 2007, 2011). 22 
In this case, we included the most recent citation which had the most participants. 23 
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Reasons for exclusion included: no clinical cut-off/diagnostic algorithm for 1 
anxiety/depression applied (n=28); study did not measure anxiety/depression (n=25); 2 
minimum age of participants was <16 years (n=11); non-ASD sample (n=9); no English 3 
translation was available (n=8); not peer reviewed (n=3), intervention study (n=1), 4 
review article (n=1).  5 
Data extraction. All data was extracted by the first author (MJH) and then a 6 
randomly selected sample of 25% of the studies were checked for accuracy (J-WL), 7 
resulting in no disagreement.  8 
Study Sample  9 
The final sample included 35 studies across both anxiety and depression, with 10 
27 studies measuring anxiety, 29 measuring depression, and 21 measuring both. 11 
Studies measuring anxiety included a total of 26,070 participants (mean age = 30.9 12 
years, SD=6.2), and for depression there were in total of 26,117 participants (mean 13 
age = 31.1 years, SD=6.8; see Tables 2 & 3 for study characteristics and summary of 14 
main findings). 15 
   INSERT TABLE 2 ABOUT HERE 16 
For three studies where the age of the sub-sample of interest was not reported,  17 
the mean was estimated based on the age of the overall sample (Morgan et al. 2003; 18 
Hermans et al. 2011; Houghton et al. 2017). Seven of the 36 studies included in the 19 
meta-analysis included adolescents in the sample (≥16 years old). Nine of the studies 20 
included had a sample that included at least 50% of people with an ID and were 21 
included in the sub-analysis described below (Buck et al. 2014; Charlot et al. 2008; 22 
Helverschou et al. 2009; Hermans et al. 2012; Mazefsky et al. 2008; McDermott et al. 23 
2005; Morgan et al. 2003; Moss et al. 2015; Tsakanikos, et al. 2011). 24 
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INSERT TABLE 3 ABOUT HERE 1 
Meta-analytic method  2 
A random-effects meta-analysis with arcsine transformation was used to 3 
account for issues with study weightings when estimating prevalence (Barendregt et 4 
al. 2013). Study heterogeneity was assessed using the I2 statistic, whereby a score of 5 
more than 50% indicates moderate, and a score of 75% high levels of heterogeneity, 6 
respectively (Higgins & Thompson 2002).  7 
Subgroup analyses were conducted to investigate differences in rates reported 8 
in studies where ≥50% of the sample had ID as compared to studies of participants 9 
without ID or with small number of individuals with ID in the sample; assessment of 10 
ASD diagnoses (i.e., using Autism Diagnostic Observation Schedule (ADOS)/ Autism 11 
Diagnostic Interview (ADI)/ other standardized diagnostic assessment for ASD versus 12 
studies not reporting standardized diagnostic procedures to confirm ASD diagnosis); 13 
and measurement of comorbidity (i.e., questionnaire versus clinical interview). A table 14 
showing the range of measures used to assess anxiety and depression and their 15 
psychometric properties can be seen in the Supplementary Materials (see 16 
Supplementary Materials 2). It was also of interest to investigate the impact of sample 17 
type (e.g., clinical versus community sampling). However, as there were few studies 18 
that could clearly be defined as non-clinical, sampling was considered under study 19 
quality.  20 
The significance of differences in pooled estimates between subgroups was 21 
assessed via meta-regression analyses. Study quality was assessed on two domains, 22 
selection bias and detection bias, which were adapted for this meta-analysis from the 23 
Effective Public Health Practice Project Quality Assessment Tool (Armijo-Olivo et al. 24 
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2012 ; see Suppementary Material). OpenMeta, a tool for running metafor package in 1 
R (Viechtbauer 2010), was used to conduct the meta-analysis (Wallace et al. 2012).  2 
Results 3 
Prevalence of anxiety disorders in adults with ASD  4 
Any anxiety disorder. Meta-analytic pooling of the estimates yielded the 5 
prevalence of any current anxiety disorder as 27% (95% CI 17% – 37%; k (number of 6 
studies)= 13, n = 431/1444). Assessment of heterogeneity indicated high levels of 7 
variance between studies included in the analysis (I2 = 96%). A subsequent analysis 8 
of the eight studies which were classified as measuring lifetime prevalence indicated 9 
a prevalence of 42% (95% CI 35% – 50%; k = 8, n = 6634/25714, I2 = 96%; see Table 10 
4).  11 
Social Anxiety. Overall 12 studies reported on rates of social anxiety, together 12 
reporting an estimated current prevalence of 29% and lifetime prevalence of 20% 13 
(current: 95% CI 18% – 40%, k = 9, n = 200/1009, I2 = 91%; lifetime: 95% CI 7% – 14 
38%, k = 5, n = 75/322, I2 = 91%). 15 
OCD. Fifteen studies in total measured the rates of OCD with current 16 
prevalence estimate of 24% and a lifetime prevalence of 22% (current: 95% CI = 15% 17 
– 33%, k = 10, n = 265/1147, I2 = 93%; lifetime: 95% CI = 10% – 27%, n = 247/2063, 18 
k = 7, I2 = 93%).  19 
GAD. Seven studies reported current GAD prevalence of 18% and lifetime 20 
prevalence of 26% (current: 95% CI 10% – 26%, k = 4, n = 138/847, I2 = 86%; lifetime: 21 
95% CI 15% – 28%, k = 4, n = 63/272, I2 = 74%).  22 
Panic/ Agoraphobia. Eight studies in total reported an estimated current and 23 
lifetime prevalence of 15% and 18%, respectively (current: 95% CI 8% – 23%, k = 4, 24 
n = 62/388, I2 = 62%; lifetime: 95% CI 10% - 27%, k = 4, n = 66/322, I2 = 75%).  25 
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PTSD. Post-traumatic stress disorder was reported in five studies with a current 1 
prevalence of 1% and lifetime prevalence of 5% was found (current: 95% CI 0% – 5%, 2 
k = 3, n = 5/587, I2 = 63%; lifetime: 95% C.I. 1% – 10%, n studies = 3, n = 12/251, I2 = 3 
67%).  4 
Specific Phobia. A total of four studies reported on rates of specific phobia 5 
yielding an estimated current prevalence of 6% and a lifetime prevalence of 31% 6 
(current: 95% CI 1% – 32%, k = 2, n = 13/537, I2 = 97%; lifetime: 95% C.I. 10% – 66%, 7 
k = 3, n = 46/218, I2 = 92%).  8 
Separation Anxiety. Current separation anxiety was reported by only one 9 
study as present in 3% of the sample (n=2/62), with a lifetime prevalence of 21% 10 
(13/62) (Joshi, et al. 2013).  11 
Sub-group analyses: the role of clinical interview versus questionnaire 12 
measures, ASD diagnostic tools and intellectual disability on current anxiety 13 
prevalence estimates  14 
Use of clinical interview versus questionnaires to measure anxiety. When 15 
comparing studies which used a structured clinical interview versus questionnaires to 16 
assess current rates of any anxiety disorder, we found no significant differences in 17 
prevalence estimates (Clinical interview: k = 7; n = 275/786, estimated prevalence = 18 
28%, 95% CI 19% – 39%, I2 = 85%; questionnaires: k = 4, n = 103/238, estimated 19 
prevalence = 31%, 95% CI 12% – 54%, I2 = 91%). However, all but one of the nine 20 
studies of current social anxiety used a structured diagnostic interview, with this one 21 
study employing a questionnaire indicating a prevalence of 51% (Spain et al. 2016) 22 
versus a pooled prevalence of 26% in the remaining studies (k = 8, n = 174/958, CI 23 
16% – 37%, I2 = 90%). 24 
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Eight studies which assessed current OCD used clinical interviews resulting in 1 
a significantly lower (β = 0.26, p = 0.03) estimated pooled prevalence of 19% versus 2 
43% from the two studies which used questionnaire measures and a reduced level of 3 
between study heterogeneity (Clinical interview: k = 8, n = 215/1050, 95% CI 13% – 4 
23%, I2 = 79%; questionnaires: k = 2, n = 50/97, 95% CI 3% - 92%, I2 = 97%).  5 
Use of ASD diagnostic tools. Only 4/13 studies of current prevalence of any 6 
anxiety disorder used the ADOS and/or ADI to confirm ASD diagnosis for inclusion 7 
into studies. The use of ADOS/ADI assessment lead to slight, but non-significant, 8 
increases in the estimated pooled prevalence (ADOS/ADI studies: k = 4, n = 223/603, 9 
estimated prevalence = 28%, 95% CI 15% – 43%, I2 = 86%; non-ADOS/ADI studies: 10 
k = 9, n = 208/841, estimated prevalence = 25%, 95% CI 13% – 37%, I2 = 95%).  11 
Similar results were found when looking at the 6/9 studies of current social 12 
anxiety (ADOS/ADI studies: k = 6, n = 159/846, estimated prevalence = 33%, 95% CI 13 
19% – 46%, I2 = 92%; non-ADOS/ADI studies: k = 3, n = 41/163, estimated prevalence 14 
= 21%, 95% CI 4% – 48%, I2 = 93%) and 5/10 studies of current OCD (ADOS/ADI: k 15 
= 5, n = 196/857, estimated prevalence = 24%, 95% CI 12% – 41%, I2 = 95%; non-16 
ADOS/ADI: k = 5, n = 69/290, estimated prevalence = 19%, 95% CI 14% – 31%, I2 = 17 
65%).  18 
Presence of intellectual disability. Subgroup analysis of studies of current 19 
prevalence of anxiety disorder or clinically elevated anxiety symptomatology of 20 
participants with or without associated ID revealed a somewhat lower, but non-21 
significant, pooled estimate of any anxiety disorder in adults with ASD and associated 22 
ID (k = 6, n = 79/394, estimated prevalence = 20%, 95% CI 7% – 39%, I2 = 93%) 23 
compared to samples including only individuals with ASD without ID (k =7, n = 24 
352/1050, estimated prevalence = 24%, 95% CI 19% – 43%, I2 = 93%).  25 
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All nine studies of current social anxiety included only participants with ASD 1 
without an intellectual disability, while only three of ten studies measuring OCD 2 
included primarily adults with ASD and ID, resulting in no significant difference in 3 
pooled prevalence estimates (ID: k = 3, n = 55/177, estimated prevalence = 24%, 95% 4 
CI 0.14 – 0.36, I2 = 49%; non-ID: k = 7, n=210/970, estimated prevalence = 20%, 95% 5 
CI 0.10 – 0.34, I2 = 93%). 6 
Prevalence of depression in adults with ASD 7 
Meta-analytic pooling of the estimates yielded a 23% prevalence of current co-8 
morbid depression diagnoses or moderate to severe clinically elevated depressive 9 
symptoms in adults with ASD (k = 22, n = 400/1975; 95% CI 17% – 29%). Assessment 10 
of heterogeneity indicated high levels of variance between studies included in the 11 
analysis (I2 = 90%).  12 
A subsequent analysis of the seven studies which were classified as measuring 13 
lifetime prevalence of depression indicated a prevalence of 37% (k = 10, n = 14 
4603/24384; 95% CI 27% – 47%; I2 = 98%). 15 
INSERT TABLE 4 ABOUT HERE 16 
Sub-group analyses: the role of clinical interview versus questionnaire 17 
measures, ASD diagnostic tools and intellectual disability on current 18 
depression prevalence estimates 19 
Use of clinical interview versus questionnaires to measure depression. 20 
When comparing studies which used a clinical interview versus questionnaires to 21 
assess depression, we found a small, but non-significant, increase in prevalence 22 
estimates for studies using a clinical interview rather than a questionnaire measure 23 
(Clinical interview: k = 11, n = 237/1182, estimated prevalence = 27%, 95% CI 18% – 24 
15 
 
37%, I2 = 92%; questionnaire: k = 8, n = 106/429, estimated prevalence = 20%, 95% 1 
CI 11% – 33%, I2 = 87%). 2 
Use of ASD diagnostic measures. Only 6/19 studies of current prevalence 3 
used the ADOS and/or ADI to assess or confirm ASD in their participants. This made 4 
little difference to prevalence estimates, but resulted in a considerable drop in 5 
heterogeneity between studies (ADOS/ADI studies: k = 6, n = 170/878, estimated 6 
prevalence = 22%, 95% CI 16% – 28%, I2 = 66%; non-ADOS/ADI: k = 15, n = 7 
214/1047, estimated prevalence = 23%, 95% CI 14% – 34%, I2 = 93%; p =.09).  8 
Presence of ID. Subgroup analysis of studies of current prevalence of 9 
depression based on whether the sample included participants with or without an ID 10 
revealed a significantly lower pooled estimate of depression in those with ASD and ID 11 
(meta-regression: β = .12, p = .03), compared to samples including only those without 12 
ID (ID: k = 6, n = 58/512, estimated prevalence = 14%, 95% CI 5% – 28%, I2 = 92%; 13 
non-ID: k = 16, n=326/1413, estimated prevalence = 26%, 95% CI 20% – 32%, I2 = 14 
83%). 15 
Evaluating the quality of included studies  16 
Our analysis of study quality revealed overall poor quality. Most prominent with 17 
regards to prevalence is the reliance on clinic samples and little data available on how 18 
representative study participants are of adults with ASD more generally. These results 19 
can be seen in Supplementary Materials 1 and indicate that there are few studies 20 
which have clearly taken measures to reduce selection and detection bias. 21 
 22 
 23 
  24 
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 1 
Discussion 2 
Summary of main findings 3 
While it is widely accepted that adults with a diagnosis of ASD are at higher risk 4 
of experiencing comorbid anxiety and depressive disorders, there has yet to be a 5 
systematic review and meta-analysis to summarise the range of estimates of 6 
prevalence available in the literature (see also Wigham et al., 2017). We found a 7 
pooled estimate of any current anxiety and depression of 27% and 23% respectively 8 
in clinical studies, considerably higher than would be expected based on estimates of 9 
1-12% in the general population (Kessler et al. 2003; 2012). The rate of current 10 
depression was consistent with the estimate of >20% reported by Wigham et al. 11 
(2017), which examined a subset of the studies included in the present meta-analysis. 12 
The finding of somewhat higher rates of anxiety compared to depression was also 13 
similar for pooled lifetime estimates of any anxiety (42%) and depression (37%). 14 
Consistent with estimates from childhood (van Steensel et al. 2011), we found that 15 
specific anxiety disorders, particularly social phobia and OCD, were more commonly 16 
present in adults with ASD. However, our analyses of both heterogeneity and study 17 
quality indicated high level of variance between studies, a wide range of study 18 
methodologies and sample selection, all of which increase the likelihood of biases and 19 
reduce our ability to make more firm estimates of prevalence from the studies currently 20 
available.   21 
Rates/ prevalence of anxiety and depression in adults with ASD 22 
The findings of the current study are consistent with meta-analyses of the 23 
prevalence of anxiety in people with ASD aged 18 years and under (van Steensel et 24 
17 
 
al. 2011; van Steensel & Heeman, 2017). However, while the 2011 meta-analytic study 1 
suggested a current rate of any anxiety disorder of around 39%, our pooled estimate 2 
of anxiety in adulthood appears lower at 27%. This may be explained by lower rates 3 
(when measured) of anxiety disorders more typically associated with the childhood 4 
period such as separation anxiety (Bögels et al. 2013), and a reduction in the 5 
estimated prevalence of specific phobias. It is notable, however, that compared to the 6 
estimates by van Steensel and colleagues, we found a near 10% higher rate of both 7 
social anxiety and OCD in adults. This could in part be accounted for by the fact that 8 
these anxiety subtypes were assessed/reported more often in the literature included 9 
in the current meta-analysis. It is also possible that these high rates could be at least 10 
partially due to diagnostic overshadowing, which is a challenge with OCD and social 11 
anxiety as discussed earlier. In fact, this was evident in our sub-group analysis 12 
comparing structured interviews and questionnaires, with the later resulting in higher 13 
estimates of both OCD and social anxiety. This may suggest that the process of 14 
eliciting a detailed description of the target behaviour, as is often the case when 15 
conducting a diagnostic or a semi-structured interview and making a clinical judgement 16 
on this may reduce the impact of diagnostic overshadowing. Similarly, this may 17 
account for the higher heterogeneity of prevalence rates based on questionnaire 18 
measures vs. structured interviews. However, it is important to note that in both 19 
methods the heterogeneity remains high. 20 
One a-priori aim of this systematic review and meta-analysis was to consider 21 
the possible impact of diagnostic overshadowing on the estimated reported prevalence 22 
of anxiety and depression in adults with ASD. Unfortunately, only four of the total of 23 
36 studies included in this meta-analysis considered diagnostic over-shadowing: two 24 
relied on clinical experience or trained research staff who conducted the interviews in 25 
18 
 
differentiating symptoms of anxiety and ASD (Capriola et al. 2016; Maddox & White 1 
2015); one used a measure specifically designed to assess comorbidity in ASD 2 
(Helverschou et al. 2008), and one removed all symptoms of OCD which potentially 3 
overlapped with those of ASD from their diagnostic coding (Buck et al. 2014). In the 4 
latter study, this resulted in the lifetime prevalence dropping from 36% to 22%, 5 
suggesting that overlap between ASD and anxiety symptomatology and presentation 6 
does to some extent impact the estimated reported prevalence and that caution should 7 
be exercised when interpreting the results of the other studies and of this meta-8 
analysis. From a clinical perspective, this finding suggests that at the current time an 9 
overreliance on informant-based or self-report questionnaire measures to assess 10 
mental health in ASD without the use of more detailed in depth structured clinical 11 
interviews is not recommended. Rather, a detailed assessment focusing explicitly on 12 
follow-up questions to clarify the nature of symptoms and to differentiate between ASD 13 
and mental health symptomatology may be warranted in clinical settings, with 14 
checklists used as supplementary or preliminary information. However, in research 15 
this must be performed in a transparently reproducible way, which so called ‘clinical 16 
consensus’ methods often make difficult. 17 
In contrast to studies in children & adolescents with ASD (Simonoff et al. 2008; 18 
Salazar et al. 2015) which report relatively low rates of depression, our current study 19 
found a high estimated pooled prevalence of 22% in adults with ASD. This suggests 20 
that mood related issues likely pose significant difficulties for many adults with ASD.  21 
Moreover, these findings may also suggest a developmental progression with 22 
depression becoming more prominent in adulthood. Interestingly, our findings suggest 23 
the prevalence of depression was 10% lower in those with compared to those without 24 
ID, suggests that current self-report measures may not be adequately assessing 25 
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symptoms of depression. This may be because of difficulties with identifying and 1 
describing low mood, which may be further exacerbated by ID or difficulties with the 2 
verbal articulation of the physiological, emotional, cognitive and behavioural 3 
experiences of depression (Hassiotis & Turk 2012). 4 
Limitations  5 
The results presented here must be considered in the context of several 6 
limitations. Due to the high heterogeneity between the studies included, it is difficult to 7 
be certain how much our current estimates reflect the true prevalence of anxiety and 8 
depression in adults with identified ASD. The high heterogeneity, while making firm 9 
conclusions regarding prevalence difficult, is a realistic presentation of the current 10 
literature on mental health comorbidities in ASD. Due to several factors, including 11 
missing data from studies, we were unable to look at other factors that may influence 12 
prevalence rates, such as age or gender ratio. For example, to explore whether rates 13 
of depression increase with age or, as suggested in the non-ASD literature, that 14 
prevalence of anxiety is higher in females than males (McLean et al. 2011).  Future 15 
meta-analyses can investigate the influence of these factors when more data from 16 
empirical studies become available.  Furthermore, there were several studies which 17 
we were unable to include due to not being able to extrapolate a prevalence rate which 18 
may have influenced the accuracy of our current estimates. In addition, due to the lack 19 
of studies which used information from multiple informants we were unable to evaluate 20 
the inter-rater reliability of diagnoses and reported prevalence rates and the rates from 21 
studies using questionnaires mostly relied on self-report data. Nevertheless, studies 22 
which did use measures completed by different informants (i.e. caregivers versus self-23 
report) suggested a reasonable overall level of agreement (Gotham et al. 2015; 24 
Maddox & White 2015), although degree of agreement did vary between studies (Buck 25 
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et al. 2014). Furthermore, there were no community studies that included adults whose 1 
ASD had not been recognised or who had not been in contact with clinical services, 2 
and therefore the samples included in the current analysis may not fully represent 3 
adults with ASD in the whole population. Accordingly, our findings should be of value in 4 
clinical practice settings but may be of more limited value to our understanding of the 5 
relationship of ASD to other forms of mental health disorders in the wider community. 6 
Implications and recommendations for future research  7 
The current analysis has identified several gaps in the literature. Future studies 8 
of prevalence should use well defined and validated diagnostic assessments to both 9 
confirm the diagnosis of ASD and to assess psychiatric comorbidity. We found no 10 
studies examining comorbidity in non-clinical (i.e. community or general population) 11 
samples of adults with ASD. The development and implementation of such studies 12 
should be a priority. In addition, the current literature does not consider difficulties with 13 
alexithymia (difficulties with labelling emotions) which are common in ASD (Bird et al. 14 
2011). Variability in symptoms of alexithymia may influence the reported levels of 15 
emotional symptoms and this should be considered in future studies. The use of 16 
standardised and validated semi-structured, investigator rated ASD diagnostic tools, 17 
such as the ADOS and ADI-R, in future prevalence studies may also help to reduce 18 
heterogeneity and strengthen the characterization of participants included in such 19 
studies. Despite the recognition of possible diagnostic overshadowing, there is a 20 
dearth of research on validated assessments of depression and anxiety in adults with 21 
ASD (Brugha et al. 2015). While across both child and adult populations there have 22 
been efforts to validate some existing questionnaires (i.e. Zainal et al. 2014; Magiati 23 
et al. 2017; Uljarevic et al. 2018) and to develop population specific tools (Bearss et 24 
21 
 
al. 2016; Rodgers et al. 2016), more research in this area is still required concerning 1 
assessment issues.  2 
Conclusion and clinical implications  3 
In conclusion, adults with a diagnosis of ASD experience high rates of comorbid 4 
anxiety and depression. The exact prevalence is difficult to estimate precisely, given 5 
high levels of heterogeneity between studies, but our results suggest rates significantly 6 
higher than one would expect. Although it is possible that depression is 7 
underestimated, especially in the context of ASD with ID, both anxiety and depression 8 
are prominent and common in adults with a diagnosis of ASD. This suggests that in 9 
clinical settings a thorough assessment of the mental health of individuals with ASD 10 
involving different methodologies and self-, in addition to other-informant, measures is 11 
warranted. Provision for access to evidence-based psychological interventions 12 
specifically adapted for this population is also important clinically (Rodgers et al, 2018; 13 
Russell et al, 2017).  As is to consider that due to the high rates of anxiety and 14 
depression in this population, as yet unidentified and undiagnosed, individuals with 15 
ASD may be over represented in mental health services. 16 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analysis 1 
(PRISMA) flowchart. 2 
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 1 
Table 1. Inclusion and exclusion criteria to be eligible for inclusion in the current systematic 2 
review 3 
Inclusion criteria  Exclusion criteria  
(i) include participants with a diagnosis 
of ASD based on either DSM or ICD 
criteria. Where the ASD diagnosis 
was not carried out using an ADOS 
or/ an ADI-R, we took an inclusive 
approach with the aim to explore the 
impact of ASD diagnostic tools on 
prevalence estimate in a sensitivity 
analysis;  
(ii) study participants, or an identifiable 
sub-group, with mean group age ≥ 
18 years with the youngest 
participant being no younger than 
16; 
(iii) include an assessment of comorbid 
anxiety or depression using either a 
diagnostic interview, or a validated 
questionnaire measure with cut-off 
scores for clinical caseness or a 
clinical diagnosis based on either 
DSM or ICD criteria; 
(iv) be published in English or have an 
English translation available. 
 
(i) Studies which had not undergone 
peer review. 
(ii) Other systematic reviews which do 
not provide new data on rates of 
anxiety or depression in adults with 
ASD. 
(iii) Single case studies or case series 
methodologies. 
(iv) Treatment trial studies looking 
specifically at interventions for co-
occurring psychiatric conditions in 
people with ASD, as these 
constituted clinical samples; 
(v) Studies which focused on genetic 
syndromes associated with ASD 
(e.g., Fragile X Syndrome, Rett 
Syndrome).  
(vi) Studies of dysthymia or bipolar 
disorder, as we focused on 
depression. 
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Table 2. Included studies assessing anxiety, study characteristics and prevalence rates of anxiety 1 
      
First 
Author 
(year) 
N Mean 
age 
Age 
range  
Male 
(%) 
ID 
(%) 
Source Ethnicity Country Meth-
od 
Respondent  Current 
/Lifetime 
Rates of Anxiety % 
            ANY ANX SOC OCD GAD PAN/ 
AGO 
SPH  SEP
. 
PTSD 
Ashwood 
(2016) 
260 32 18-70 NR 0 Clin NR London, 
UK 
I Self-report Current  NR 18 24 23 16 NR NR NR 
Bejerot 
(2014) 
50 30 28-36 52 0 Clin NR Sweden I Self-report Current  NR 28 NR NR NR NR NR NR 
Buck (2014) 
129 36 26-54 75 73 Com NR Utah, 
USA 
I Self-report Current / 
Lifetime 
40/53 NR 33/36 NR NR NR NR NR 
Capriola 
(2016) 
18 25 18-44 56 0 NT 16 
Caucasian 
2 Others 
(multi, 
Asian) 
Virginia, 
Philadel
phia, 
USA 
I Self-report Current  NR 61 NR NR NR NR NR NR 
Charlot 
(2008) 
13 39 NR 62 100 Clin NR Massac-
husetts, 
USA 
I Informant Current  NR NR 46 NR NR NR NR NR 
Croen 
(2015) 
1507 29 18-
65+ 
73 19 Clin 988 White, 
non- 
Hispanic 
 
59 White, 
Hispanic 
 
460 
Others 
[Black 115 
Asian 168 
Other 177] 
Californi
a, USA 
C Clinical records  Lifetime  29 NR 8 NR NR NR NR NR 
Ghaziuddin 
(2008) 
28 27 18-57 64 7 Clin NR Michiga
n, USA 
I Self-report Current  21 NR NR NR NR NR NR NR 
Gillberg 
(2016) 
50 30 23-43 100 0 Clin NR Gothenb
urg, 
Sweden 
I Self-report Current  22 4 8 10 6 NR NR 0 
Helverschou 
(2009) 
35 35 17-56 74 100 Clin NR Oslo, 
Norway 
Q Informant  Current 17 NR 17 NR NR NR NR NR 
Hermans 
(2012) 
46 NR NR NR 100 Clin NR The 
Netherla
nds 
I Self-report Current  11 NR NR NR NR NR NR NR 
Hofvander 
(2009) 
122 27 16-60 67 0 Clin NR Paris, 
France 
I Self-report Lifetime  48 NR 24 NR NR NR NR NR 
37 
 
&  
Gothenb
urg, 
Sweden 
Houghton 
(2017) 
22253 NR 18-
50+ 
80 26 Clin  Only 
available 
for 
medicaid 
dataset  
46,696 
 
White 
23,404 
(50.12) 
Black 
8,792 
(18.83) 
Hispanic 
1,909 
(4.09) 
Other 
12,591 
(26.96) 
USA C Clinical records Lifetime 25 NR NR NR NR NR NR NR 
Jones 
(2014) 
120 39 18-76 58 0 NT NR London, 
UK 
Q Self-report Current 57 NR NR NR NR NR NR NR 
Joshi (2013) 
63 29 18-63 65 0 Clin 55  
Caucasian 
Massac
husetts, 
USA 
I Self/Informant Current/Lif
etime 
NR 40/56 16/24 29/35 24/35 18/32 3/21 5/11 
Ketelaars 
(2008) 
15 22 18-24 80 0 Clin NR The 
Netherla
nds 
I Self-report Current NR 20 7 NR 13 NR NR NR 
Lai (2011) 
62 27 18-45 53 0 NT NR England 
and 
Wales 
Q Self-report Current 44 NR 71 NR NR NR NR NR 
Lever (2016) 
138 47 19-79 70 0 Clin NR The 
Netherla
nds 
I Self-report Lifetime 54 15 22 16 21 12 NR 3 
Lugnegard 
(2011) 
54 27 NR 48 0 Clin NR Karlstad, 
Sweden 
I Self-report Lifetime 56 22 7 22 15 NR NR NR 
Maddox 
(2015) 
28 24 16-42 54 0 NT Caucasian 
22 
Hispanic/L
atino: 1 
Others: 5  
Virginia  
USA 
I Self-report Current  NR 50 NR NR NR NR NR NR 
Mazefsky 
(2008) 
16 25 18-32 94 70 Com NR Marylan
d USA 
I Informant Lifetime  77 0 NR 41 0 59 NR NR 
Moss (2015) 
21 43 29-64 83 0 Clin NR London 
UK 
Q Self-report Current  10 NR 29 NR NR NR NR NR 
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Note. ID= Intellectual Disability Disorder; Com= Recruited from a whole community or community sampling strategy was used; Clin= Recruited through a clinical service; NT= Non-treatment seeking 1 
and recruited through notices or databases, but not due to clinical contact; I= Structured Interview, Q= Standardised Questionnaire, C= Clinical Records or not reported; ANY ANX= Any Anxiety 2 
Disorder; SOC= Social Anxiety Disorder; OCD= Obsessive-compulsive Disorder; GAD= Generalised Anxiety Disorder; PAN/AGO= Panic Disorder/ Agoraphobia; SPH= Specific Phobia; SEP= 3 
Separation Anxiety Disorder; PTSD = Post-traumatic Stress Disorder, NR = not reported.  4 
Nylander 
(2013) 
270 27 16-63 69 12 Clin NR Sweden C Clinical records Current  17 NR NR NR NR NR NR NR 
Roy (2015) 
50 37 20-62 68 0 Clin NR German
y 
I Self-report Lifetime NR 12 14 NR 14 NR NR 2 
Russell 
(2016) 
474 31 18+ 78 0 Clin NR London, 
UK 
I Self-report Current  39 12 18 12 4 0.4 NR 0.4 
Spain 
(2016) 
50 26 18+ 100 0 Clin Majority 
‘White 
European’. 
South-
east 
England, 
UK 
Q Self-report Current NR 52 NR NR NR NR NR NR 
Sterling 
(2008) 
46 24 18-44 91 0 Clin 44 Non-
Hispanic 
or 
White,  
 
2 Others: 
(1 African 
American, 
1 more 
than one 
race) 
Washing
ton, 
USA 
I Self-report Current  17 NR 9 NR NR NR NR NR 
Tsakanikos 
(2011) 
150 29 16-84 67 100 Clin NR South 
East 
London, 
UK 
C Clinical records Current  5 NR NR NR NR NR NR NR 
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Table 3. Included studies assessing depression, study characteristics and prevalence rates of depression 1 
Author (year) N Mean age Age 
range  
Male (%) ID (%) Source Ethnicity Country Method Respondent  Current/
Lifetime 
Rates of 
Depression (%) 
Ashwood (2016) 
260 32 18-70 NR 0 Clin NR London, 
UK 
I Self-report Current  20 
Berthoz (2013) 38 36 28-36 63 0 NT NR UK Q Self-report Current 32 
Buck (2014) 
129 36 26-54 75 73 Com NR Utah, 
USA 
I Self-report Current / 
Lifetime 
<1/13 
Cederlund (2010) 
76 22 16-37 100 NR Clin NR Goteborg
, Sweden 
Q Self-report Current  4 
Charlot (2008) 
13 39 NR 62 100 Clin NR Massach
usetts, 
USA 
I Informant Current  69 
Crane (2013) 
28 42 NR 50 0 NT NR London, 
UK 
Q Self-report Current  36 
Croen (2015) 
1507 29 18-65+ 73 19 Clin 988 
White, 
non-
Hispanic 
 
59 White, 
Hispanic 
 
460 
Others 
[Black 
115 
Asian 
168 
Other 
177] 
California
, USA 
C Clinical records  Lifetime  26 
Ghaziuddin (2008) 
28 27 18-57 64 7 Clin NR Michigan, 
USA 
I Self-report Current  50 
Gillberg (2016) 
50 30 23-43 100 0 Clin NR Gothenb
urg, 
Sweden 
I Self-report Current / 
Lifetime 
4/32 
Gotham (2015) 
50 21 16-31 90 0 Clin 82% / 41 
Caucasia
n (n = 
41),  
 
North 
Carolina, 
Chicago, 
Michigan, 
USA 
Q Self-report Current  20 
40 
 
9 Others 
(12% 
 / 6 
African 
American
, 1 
Asian/Pa
cific 
Islander, 
1 
American 
Indian, 1 
“two or 
more 
racial 
affiliation
s 
Hedley (2017) 
76 25 17-56 91 10 NT 66 
(86.8%) 
Australia
n  
8 
(10.5%) 
Other 
2 (2.6%) 
Prefer 
not to 
answer  
Australia Q Self-report Current 25 
Helverschou (2009) 
35 35 17-56 74 100 Clin NR Oslo, 
Norway 
Q Informant  Current 14 
Hill (2004) 27 35 16-63 56 0 NT NR UK Q Self-report Current  22 
Hofvander (2009) 
122 27 16-60 67 0 Clin NR Paris, 
France &  
Gothenb
urg, 
Sweden 
I Self-report Lifetime  53 
Houghton (2017 
22253 NR 18-50+ 80 25 Clin Only 
available 
for 
medicaid 
dataset  
46,696 
USA C Clinical records Lifetime  18 
41 
 
 
White 
23,404 
(50.12) 
Black 
8,792 
(18.83) 
Hispanic 
1,909 
(4.09) 
Other 
12,591 
(26.96) 
Jones (2014) 
120 39 18-76 58 0 NT - London, 
UK 
Q Self-report Current 42 
Joshi (2013) 
63 29 18-63 65 0 Clin 55  
Caucasia
n 
Massach
usetts, 
USA 
I Self/Informant Current/L
ifetime 
31/77 
Ketelaars (2008) 
15 22 18-24 80 NR Clin NR The 
Netherla
nds 
I Self-report Current 26 
Lai (2011) 
62 27 18-45 53 0 NT NR England 
and 
Wales 
Q Self-report Current 27 
Lever (2016) 
138 47 19-79 70 0 Clin NR The 
Netherla
nds 
I Self-report Lifetime 53 
Lugnegard (2011) 
54 27 NR 48 0 Clin NR Karlstad, 
Sweden 
I Self-report  Lifetime 70 
Mazefsky (2008) 
16 25 18-32 94 70 Com NR Maryland 
USA 
I Informant Lifetime  24 
McDermot (2005) 
51 27 NR 78 0 Clin 29.4 
African 
American
, Rest 
are 
Spanish 
spaeakin
g/Asian / 
Caucasia
n 
Carolina, 
USA 
C Clinical records Lifetime  6 
Morgan (2003) 
164 NR NR 56 100 Com NR Birmingh
am, UK 
C Clinical records Current  20 
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Moss (2015) 
21 43 29-64 83 0 Clin NR London 
UK 
Q Self-report Current  10 
Roy (2015) 50 37 20-62 68 0 Clin NR Germany I Self-report  Lifetime 48 
Russell (2016) 
474 31 18+ 78 0 Clin NR London, 
UK 
I Self-report Current  16 
Sterling (2008) 
46 24 18-44 91 0 Clin 44 Non-
Hispanic 
or 
White,  
 
2 Others: 
(1 African 
American
, 1 more 
than one 
race) 
Washingt
on, USA 
I Self-report  Current  33 
Tsakanikos (2011) 
150 29 16-84 67 100 Clin NR South-
East 
London, 
UK 
C Clinical records Current  7 
Note. ID= Intellectual Disability Disorder; Com= Recruited from a whole community or community sampling strategy was used; Clin= Recruited through a clinical service; NT= 1 
Non-treatment seeking and recruited through notices or databases, but not due to clinical contact; I= Structured Interview, Q= Standardised Questionnaire, C= Clinical Records 2 
or not reported. NR = not reported. 3 
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Table 4. Pooled estimates of current and lifetime anxiety and depression in adults with ASD  1 
Diagnosis  Current/ Lifetime No. of Studies Participants, n Prevalence, % 95% C.I. I2, % 
Any anxiety  Current  13 1444 27% 17% - 37% 96% 
 Lifetime 8 25714 42% 35% - 50% 96% 
Social phobia Current  9 1009 29% 18% - 40% 91% 
 Lifetime 5 322 20% 7% - 38% 91% 
OCD Current  10 1147 24% 15% - 33% 93% 
 Lifetime 7 2063 22% 10% - 27% 93% 
GAD Current  4 847 18% 10% - 26% 86% 
 Lifetime 4 272 26% 15% - 28% 74% 
Panic/agoraphobia Current  4 388 15% 8% - 23%  62% 
 Lifetime 4 322 18% 10% - 27%  75% 
Specific phobia Current  2 537 6% 1% - 32% 97% 
 Lifetime 3 218 31% 10% - 66% 92% 
PTSD Current  3 587 1% 0% - 5% 63% 
 Lifetime 3 251 5% 1% - 10% 67% 
Separation Anxiety Current 1 63 3% - - 
 Lifetime 1 63 21% - - 
Depression  Current  22 1975 23% 17% - 29%  90% 
 Lifetime 10 24384 37% 27% - 47% 98% 
2 
44 
 
Supplementary Materials 1. Quality assessment of studies included in meta-analysis  1 
Methods 2 
Our assessment of study quality was adapted from the Effective Public Health 3 
Practice Project Quality Assessment Tool (Armijo-Olivo et al. 2012) and included an 4 
assessment of both selection and detection bias, two factors particularly relevant to 5 
studies of prevalence. Specific adaptation to the criteria where made to address the 6 
specific research question and target population. There was an emphasis placed on 7 
the tools used to assess and diagnose ASD and the target comorbidities.  To assess 8 
the quality of studies, selection criteria were developed to evaluate studies on their 9 
use and reporting of standardised diagnostic assessments of ASD. The use of a 10 
standardised structured diagnostic assessment was rated as good, using other clinical 11 
assessments (i.e. questionnaire or screening measures) were rated as satisfactory; 12 
and a historical diagnosis (i.e., medical file review) or an unconfirmed historical self-13 
reported diagnosis were rated as poor.  An additional focus of the evaluation of 14 
detection bias was the quality of measures used to assess comorbid anxiety and 15 
depression. As with the ASD diagnosis, the use of a standardised structured 16 
assessment to measure psychiatric comorbidities was rated as good; the use of a 17 
questionnaire-based measure cut-off score was rated as satisfactory, and diagnosis 18 
based on medical records only (or self-report) as poor. The criteria used to assess 19 
quality are outlined below in Table SM1.  20 
  21 
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 1 
Table SM1. Criteria Quality Analysis Ratings of Study Selection and Detection Bias   2 
 Selection Bias Detection bias 
Key Participant 
selection 
Participant 
Representation 
ASD assessment Researcher 
blinding 
Comorbidity 
assessment 
Participant 
blinding 
 How were 
participants 
selected? 
What 
percentage of 
those 
approached / 
population 
participated? 
How was ASD 
diagnosis 
assessed/ 
confirmed? 
Were 
researches 
blinded to 
participant 
clinical 
history / 
research 
aims 
What type of 
measure/assessment 
was used to assess 
anxiety or 
depression? 
Were 
participants 
aware of 
research 
question?  
Good Community  
Sample  
80 – 100% ADOS/ADI (other 
structured 
assessment) 
Yes Structured interview / 
assessment  
No 
Satisfactory  Non-
treatment 
seeking  
60 – 79%  Clinical diagnosis / 
judgment  
No Questionnaire  Yes 
Poor Clinical  
 
 
Less than 60% 
/ cannot tell 
Historic diagnosis / 
cannot tell  
Cannot tell Clinical records/ 
Cannot tell 
Cannot tell 
 3 
Each paper was reviewed by two authors (MJH & J-WL) and any disagreement were 4 
discussed and reviewed based on the criteria in Table SM1. There were four points 5 
of contention in total with all being resolved after discussion.  6 
Results  7 
As can be seen in Table SM2 below, studies were rated on six domains as 8 
either good (green), satisfactory (yellow) or poor (red). Most of the studies where 9 
rated as primarily poor in quality in the different domains assessed. Only ten of the 10 
31 studies used a structured ASD assessment to confirm participants’ ASD 11 
diagnoses. The domains in which most studies were scored as poor were participant 12 
selection and blinding. While these are important factors when considering estimates 13 
of prevalence, it is worth noting that most of the studies included in this meta-14 
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analysis were limited by the fact that they were not originally designed as prevalence 1 
studies.    2 
Table SM2. Results of Quality Analysis of Study Selection and Detection Bias   3 
 Selection Bias Detection bias 
First author (date) Participant 
selection 
Participant 
Represent-
tation   
ASD 
assessment  
Researcher 
blinding  
Comorbidity 
assessment   
Participant 
blinding   
Ashwood (2016) 
      
Bejerot (2014) 
      
Berthoz (2013) 
      
Buck (2014) 
      
Capriola (2016) 
      
Cederlund (2010) 
      
Charlot (2008) 
      
Crane (2011) 
      
Croen (2015) 
      
Ghaziuddin (2008) 
      
Gillberg (2016) 
      
Gotham (2015) 
      
Hedley (2017) 
      
Helversc. (2009) 
      
Hermans (2012) 
      
Hill (2004) 
      
Hofvander (2009) 
      
Houghton (2017) 
      
Jones (2014) 
      
Joshi (2013) 
      
Ketelaars (2008) 
      
Lai (2011) 
      
Lever (2016) 
      
Lugnegard (2011) 
      
Maddox (2015) 
      
Mazefsky (2008) 
      
McDermot (2005) 
      
Morgan (2003) 
      
Moss (2015) 
      
Nylander (2013) 
      
Roy (2015) 
      
Russell (2016) 
      
Spain (2017) 
      
Sterling (2008) 
      
Tsakanikos (2011) 
      
 4 
 5 
47 
 
Supplementary Materials 2 – Table of measures used to assess anxiety and depression in 1 
studies included in the meta-analysis  2 
Measure  Psychometrics properties Studies  
Structured/Semi-structured Interview measures  
The Mini-International Neuropsychiatric 
Interview (M.I.N.I.) (Sheehan et al., 1998) 
This is a short structured diagnostic interview 
that evaluates whether the individual meets 
psychiatric disorders’ criteria based on the 
DSM-IV and ICD-10 
Not validated in ASD sample.  
 
In typically developing adults: 
Good inter-rater and test–retest 
reliability  
 
Adequate sensitivity and 
specificity across most 
diagnoses.  
 
(Lecrubier et al. 1997; Sheehan 
et al. 1997). 
Bejerot (2014), 
Gillberg (2016), 
Lever (2016) 
Psychiatric Assessment Schedule for Adults 
with a Developmental Disability (PAS-ADD) 
(Moss et al., 1993) 
 
This semi-structured interview is designed to 
be suitable for adults with intellectual 
disability and assesses for both current 
(preceding 4 weeks) and lifetime presence of 
common psychiatric disorders based on ICD-
10. 
 
Not validated in ASD sample.  
 
In adults with intellectual 
developmental disorders: 
Satisfactory inter–rater reliability 
of the lCD–10 version (Kappa≥ 
of 0.65 for individual item and 
clinical significance of the 
symptoms) 
 
Satisfactory validity for 
depressive disorder, but weak 
validity for anxiety disorder. 
 
(Costello et al. 1997; Moss et 
al., 1997) 
Hermans 2012 
Mini PAS-ADD2 
 
This shortened version is suitable for staff 
without a background in psychiatry or 
psychology.  
 
 
Not validated in ASD sample.  
 
In adults with intellectual 
developmental disorders: 
Good internal consistency (.48–
.95) and inter-rater reliability 
(.77–.91) 
 
Satisfactory sensitivity 
(62–100%) and specificity (71–
100 %) 
 
(Devine et al. 2009; Prosser et 
al. 1998). 
 
Buck (2014) 
The Mood and Anxiety Semi-Structured 
(MASS) Interview (Charlot et al., 2007) 
 
It contains 29 questions relating to the 
presence of DSM-IV symptom criteria for 
mood and anxiety disorders and is designed 
for easy administration to individuals with 
intellectual disorder. Each symptom item is 
accompanied with a few behavioural 
examples, in which administer has to 
determine if a similar dysfunctional change is 
present.    
Not validated in ASD sample.  
 
In adults with intellectual 
developmental disorders: 
Satisfactory agreement (Kappa 
= 0.42-0.78 with comprehensive 
clinical 
evaluation and Hamilton 
Depression Rating Scale cutoff) 
 
(Charlot et al., 2007) 
Charlot (2008) 
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Structured Interview for DSM (SCID) (First, 
Gibbon, Spitzer, & Williams, 1996, First & 
Gibbon, 2004; Wittchen et al. 1997) 
 
This semi-structured clinical interview 
assesses for the presence of major DSM-IV 
Axis I diagnoses.  
 
Not validated in ASD.  
 
In typically developing adults: 
Satisfactory Test-retest reliability 
(Kappas≥.44) 
Good Inter-rater reliability  
(Kappas≥.63) 
 
 
Hofvander 
(2009), Joshi 
(2013), 
Lugnegard 
(2011),  
 
German 
version:  
Roy (2015) 
Schedule for Clinical Assessment in 
Neuropsychiatry (SCAN-2.1, Giel & Nienhuis, 
1996; World 
Health Organisation, 1992)  
 
This is a structured interview that assesses 
for mental illness, which could be used to 
match the diagnostic criteria in either ICD-
10 or DSM-IV. 
 
Not validated in ASD.  
 
In typically developing adults: 
Test-retest κ = 0.62 
94% agreement on caseness 
between interviewers (Rijnders 
et al, 2000). 
 
Ketelaars 
(2008) 
Schedule of Affective Disorders and 
Schizophrenia - Lifetime version (SADS-L; 
Endicott & Spitzer, 1978) 
 
This is a semi-structured diagnostic interview 
that involves questions regarding the peak 
severity of the current presentation, severity 
of various common psychological disorders 
in the preceding week, and psychosocial 
functioning history.   
 
 
Used previously by Lainhart 
(2003) and shown to be effective 
in people with ASD.  
 
Psychometric properties not 
commonly reported for adult 
version.  
Mazefsky 
(2008) 
Family History - Research Diagnostic Criteria 
 
It is a Family History Interview (Rutter and 
Folstein, 1995) augmented with research 
diagnostic criteria (Andreasen et al. 1977). 
This interview inquiry the parents of 
participants about their and relatives’ 
experiences of presenting psychiatric 
illnesses. The specific probes for each 
question and coding were based on DSM-IV 
(APA, 1994) definitions. 
Not reported   Sterling (2008) 
Anxiety Disorders Interview Schedule (ADIS) 
-Social anxiety section (Brown et al. 1994) 
 
A semi-structured diagnostic interview to 
assess for anxiety disorders in adults. 
Validated for children with ASD 
(intraclass correlation = 0.85-
0.98, κ = 0.67-0.91) but not 
adults (Kerns et al, 2016).  
 
 
 
 
Maddox (2015) 
Questionnaire Measures  
Beck Anxiety Inventory (Beck et al., 1988) 
 
This questionnaire contains 21 items on 
anxiety symptoms and measures the severity 
of the anxiety in the past week. Those who 
scored 26 and above were considered as 
possibly having severe anxiety. 
Not validated in ASD population.  
 
In typically developing adults: 
Excellent Internal consistency 
(Cronbach’s a=0.92) 
 
Jones (2014), 
Kleinhans 
(2016), Lai 
(2011),  
Moss (2015) 
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Satisfactory Test-retest reliability 
(1 week r= 0.75  
 
Good convergent validity 
(Moderate correlation with 
Revised Hamilton Anxiety 
Rating Scale= .51), 
 
Good convergent validity (low 
correlation with Hamilton 
Depression Rating Scale=.25)  
 
(Beck et al., 1988) 
Beck Depression Inventory (BDI) (Beck et al., 
1961). 
 
This 21 item questionnaire measures the 
degree of emotional, behavioural and 
physiological changes related to depression 
over the past week. A score of 20 indicated 
clinical caseness for typically developing 
adults.  
 
Not validated in ASD population. 
 
In typically developing adults: 
Excellent internal consistency 
(mean Cronbach's α=0.86) 
 
High validity 
(high correlation ≥ .72with 
Hamilton Psychiatric Rating 
Scale for Depression) 
 
(Beck et al., 1988) 
 
Berthoz (2013), 
Cederlund 
(2010, Hill 
(2004),  
Jones (2014),  
Lai (2011), 
Crane (2013) 
BDI-II (Beck et al., 1996) 
 
This is a revised version of BDI which 
excluded items, such as body image, 
hypochondria, and extended the timeframe to 
2 weeks to match the DSM-IV diagnostic 
criteria.  
In youths and adults with ASD: 
High internal consistency 
(Cronbach׳s α =.87) 
 
High convergent validity 
(high correlation r= .62 to .82 
with other self-reports; moderate 
correlaton with parent-rated 
Children’s Depression Rating 
Scale)  
 
Good Divergent Validity 
(low correlation with age and 
verbal IQ=-.12 to .27) 
 
(Gotham et al., 2015) 
 
In typically developing adults: 
High internal consistency 
(Cronbach's α =0.92) 
 
High convergent validity 
 
 (Dozois et al., 1998).  
Gotham (2015), 
Kleinhans 
(2016), Moss 
(2015) 
Liebowitz Social Anxiety Scale (Liebowitz, 
1987) 
 
It contains 24 items that measures the level 
of fear and extent of avoidance in common 
social situations (13 items relating to 
performance anxiety and 11 items relating to 
social interaction anxiety). A total score of 60 
or more suggested a possibility of 
generalised social anxiety disorder.  
Not validated for ASD 
population. 
 
In typically developing adults: 
Good test-retest reliability and 
Internal consistency 
(Cronbach׳s α = 0.83 to 0.95) 
 
Good convergent validity  
Spain (2016) 
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(High correlation with other 
related measures >.60; high 
correlation with clinician-
administered version = .85) 
 
Good divergent validity 
(low correlation with BDI & 
HRSD ≤.48) 
 
(Baker et al., 2001, Fresco et al., 
2001) 
Brief Fear of Negative Evaluation 
Questionnaire (Leary, 1983) 
 
This is a shortened version of the FNE 
questionnaire (Watson and Friend 1969), 
which requires participants to rate the extent 
in which each of the 12 items on concerns 
about others’ negative evaluation are 
representative of them.   
Not validated in ASD population.  
 
In typically developing adults: 
The BFNE has high correlation 
with the original FNE (.96) 
 
Excellent internal consistency 
(Cronbach׳s α = .90) and 2-
week Test-retest reliability 
(r=.94) 
 
Acceptable Convergent Validity 
(correlation with other self-
reports = .35 to .56) 
 
Acceptable Divergent Validity 
(correlation with BDI and Anxiety 
Sensitivity scale = .27 to .47, but 
moderate correlation with .51 
with Penn State Worry 
Questionnaire) 
 
(Collins et al., 2005; Weeks et 
al., 2005) 
Capriola (2016) 
Obsessive Compulsive Inventory – Revised 
(OCI-R; Foa et al., 2002) 
 
The OCI-R is a shortened version of the self-
report OCI (Foa, Kozak, Salkovskis, Coles, & 
Amir, 1998). This 18-item inventory assesses 
for symptoms of Obsessive-Compulsive 
Disorder (OCD). The total score of 21 or 
more indicates the likely clinical severity of 
OCD. 
Not validated in ASD population.  
 
In typically developing adults: 
The OCI-R correlates very 
strongly with the original version 
(r = .98), 
 
Excellent internal consistency 
(Cronbach׳s α =.81) 
 
Excellent two-week test–retest 
reliability (r=.82) 
 
Satisfactory convergent validity  
(moderate-to-high correlation 
with Y-BOCS .53, Maudsley 
Obsessive–Compulsive 
Inventory 
.85), and the PI-WSUR (.75) 
 
Poor divergent validity  
(moderate correlation with  
Hamilton Depression Rating 
Scale .58 and BDI .70) 
 
Lai (2011) 
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Satisfactory Sensitivity (65.6%) 
and specificity (63.9%) 
 
(Foa et al., 2002) 
Patient Health Questionnaire-9 (PHQ-9; 
Kroenke et al., 2001) 
 
This is a 9-item self-report questionnaire that 
measures the severity of depression. It has a 
cut off of 10 for item1 to 8.  
Not validated in ASD population.  
 
In typically developing adults: 
Good internal consistency 
(Cronbach's α =.86 and .89) 
 
Excellent Sensitivity (95%) and 
Specificity (70%)  
 
Good convergent validity 
(High correlation with BDI = .73) 
 
(Kroenke et al., 2009; Martin et 
al., 2006) 
Hedley (2017) 
Psychopathology in Autism Checklist (PAC) 
 
This 42-item checklist that are reviewed by a 
group of expert clinicians to facilitate the 
diagnosis discrimination between autism and 
four major psychiatric disorders (psychosis 
(10 items), depression (7 items), anxiety 
disorder (6 items) and OCD (7 items) based 
on DSM-IV and ICD-10. 
In adults with ASD: 
 
Anxiety: 
Good degree of interrater 
agreement. Kappa = .58 
between familiar staff or family 
member  
 
Good internal consistency: 
(Cronbach’s a = .78) 
 
Depression:  
Good degree of interrater 
agreement. Kappa = .67  
 
Good internal consistency: 
(Cronbach’s a = .85) 
Helverschou 
(2009) 
Yale–Brown Obsessive Compulsive Scale 
(Y-BOCS) (Goodman et al., 1989). 
 
This 10-item clinician-rated scale measures 
the severity of obsessive-compulsive 
behaviours. A cut off of total score between 
16–23 represents a possible moderate OCD, 
24–31 a severe disorder and >31 as an 
extreme severity).  
Not validated in ASD population.  
 
In typically developing adults: 
Good internal consistency  
(Cronbach’s a=.69-.89) and 
interrater reliability 
(ICC=.93-.96) 
 
Satisfactory convergent validity 
(Moderate correlation with 
Maudsley Obsessional-
Compulsive Inventory, 
subjective ratings of fear and 
ritual composite r=.38-.64) 
Good divergent validity 
(Non-significant correlation with 
gender, age and socioeconomic 
status and low correlation with 
anxiety subscale of symptom 
checklist r=.23-.37, but 
moderately correlated with 
depression subscale .42-.51). 
 
(Goodman et al., 1989; Woody 
et al. 1995). 
Moss (2015) 
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Note. Psychometric properties presented are based on typical adult population unless otherwise 1 
stated.  2 
  3 
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